Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + bendamustine frontline therapy in frail elderly patients with diffuse large B-cell lymphoma
2011-001421-24Phase 2Active
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and bendamustine in diffuse large B-cell lymphoma (DLBCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Complete response rate. Started Dec 2011; status: active.
02
Drugs
rituximabbendamustine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2011-001421-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001421-24.